These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 29167470)

  • 1. Glucagon-like peptide-1 mimetics, optimal for Asian type 2 diabetes patients with and without overweight/obesity: meta-analysis of randomized controlled trials.
    Zhang F; Tang L; Zhang Y; Lü Q; Tong N
    Sci Rep; 2017 Nov; 7(1):15997. PubMed ID: 29167470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Zhang F; Tong Y; Su N; Li Y; Tang L; Huang L; Tong N
    J Diabetes; 2015 May; 7(3):329-39. PubMed ID: 25043423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Overweight/Obese and/or T2DM Adolescents: A Meta-analysis Based on Randomized Controlled Trials.
    Dai M; Dai S; Gu L; Xiang Z; Xu A; Lu S; Yang Y; Zhou C
    J Clin Res Pediatr Endocrinol; 2024 Sep; 16(3):323-333. PubMed ID: 38828884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
    BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis.
    Kim YG; Hahn S; Oh TJ; Park KS; Cho YM
    Diabetes Obes Metab; 2014 Oct; 16(10):900-9. PubMed ID: 24655583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials.
    Liu Y; Ruan B; Jiang H; Le S; Liu Y; Ao X; Huang Y; Shi X; Xue R; Fu X; Wang S
    Am J Clin Nutr; 2023 Sep; 118(3):614-626. PubMed ID: 37661106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide-1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity-a systematic review and network meta-analysis.
    Shamim MA; Patil AN; Amin U; Roy T; Tiwari K; Husain N; Kumar J; Chenchula S; Rao P; Ganesh V; Varthya SB; Singh S; Shukla R; Rastogi A; Gandhi AP; Satapathy P; Sah R; Padhi BK; Dwivedi P; Khunti K
    Diabetes Obes Metab; 2024 Oct; 26(10):4302-4317. PubMed ID: 39044306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exenatide in obese or overweight patients without diabetes: A systematic review and meta-analyses of randomized controlled trials.
    Su N; Li Y; Xu T; Li L; Kwong JS; Du H; Ren K; Li Q; Li J; Sun X; Li S; Tian H
    Int J Cardiol; 2016 Sep; 219():293-300. PubMed ID: 27343423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Nowrouzi-Sohrabi P; Rezaei S; Jalali M; Ashourpour M; Ahmadipour A; Keshavarz P; Akbari H
    Eur J Pharmacol; 2021 Feb; 893():173823. PubMed ID: 33352183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.
    Fujishima Y; Maeda N; Inoue K; Kashine S; Nishizawa H; Hirata A; Kozawa J; Yasuda T; Okita K; Imagawa A; Funahashi T; Shimomura I
    Cardiovasc Diabetol; 2012 Sep; 11():107. PubMed ID: 22973968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is insulin the most effective injectable antihyperglycaemic therapy?
    Buse JB; Peters A; Russell-Jones D; Furber S; Donsmark M; Han J; MacConell L; Maggs D; Diamant M
    Diabetes Obes Metab; 2015 Feb; 17(2):145-51. PubMed ID: 25323312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus.
    Tsukamoto S; Tanaka S; Yamada T; Uneda K; Azushima K; Kinguchi S; Wakui H; Tamura K
    Diabetes Obes Metab; 2024 Jan; 26(1):262-274. PubMed ID: 37828829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis.
    Ma H; Lin YH; Dai LZ; Lin CS; Huang Y; Liu SY
    BMJ Open; 2023 Mar; 13(3):e061807. PubMed ID: 36882248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression.
    Katout M; Zhu H; Rutsky J; Shah P; Brook RD; Zhong J; Rajagopalan S
    Am J Hypertens; 2014 Jan; 27(1):130-9. PubMed ID: 24263424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Beyond glycemic control in type 2 diabetes. Promises and gambles of therapy with glucagon-like peptide-1 receptor agonists].
    Mannucci E
    G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):3-4. PubMed ID: 22158420
    [No Abstract]   [Full Text] [Related]  

  • 18. Glucagon-like peptide-1 receptor agonist and new-onset diabetes in overweight/obese individuals with prediabetes: A systematic review and meta-analysis of randomized trials.
    Yanto TA; Vatvani AD; Hariyanto TI; Suastika K
    Diabetes Metab Syndr; 2024 Jun; 18(6):103069. PubMed ID: 38963997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients.
    Feng P; Yu DM; Chen LM; Chang BC; Ji QD; Li SY; Zhu M; Ding SH; Zhang BZ; Wang SL; Li HT; Lin JN; Wang MJ; Guo JC; Liu J; Liu ZD; Wu ST; Yang JH
    Acta Pharmacol Sin; 2015 Feb; 36(2):200-8. PubMed ID: 25619391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trial.
    Sargeant JA; King JA; Yates T; Redman EL; Bodicoat DH; Chatterjee S; Edwardson CL; Gray LJ; Poulin B; Waheed G; Waller HL; Webb DR; Willis SA; Wilding JPH; Khunti K; Stensel DJ; Davies MJ
    Diabetes Obes Metab; 2022 Aug; 24(8):1509-1521. PubMed ID: 35441435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.